J. Safra Sarasin Holding AG Buys Shares of 5,967 Humana Inc. (NYSE:HUM)

J. Safra Sarasin Holding AG purchased a new position in Humana Inc. (NYSE:HUM) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 5,967 shares of the insurance provider’s stock, valued at approximately $1,514,000.

A number of other institutional investors have also made changes to their positions in the stock. Dodge & Cox grew its position in shares of Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock worth $2,587,345,000 after buying an additional 5,264,045 shares during the period. Vanguard Group Inc. grew its holdings in Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after purchasing an additional 1,751,857 shares during the period. Norges Bank acquired a new position in Humana during the fourth quarter valued at approximately $416,202,000. Pzena Investment Management LLC increased its stake in Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after purchasing an additional 1,103,132 shares in the last quarter. Finally, Boston Partners raised its holdings in Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock worth $279,236,000 after purchasing an additional 893,637 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of recent analyst reports. Piper Sandler upped their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Robert W. Baird raised their price target on Humana from $270.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 15th. Mizuho boosted their price objective on Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a research report on Wednesday, April 9th. Guggenheim started coverage on shares of Humana in a report on Wednesday, April 9th. They set a “buy” rating and a $326.00 target price on the stock. Finally, JPMorgan Chase & Co. reduced their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Seventeen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus price target of $284.90.

Humana Trading Up 5.3 %

NYSE HUM opened at $258.87 on Wednesday. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a 50 day moving average of $265.74 and a 200-day moving average of $270.19. The company has a market cap of $31.24 billion, a PE ratio of 26.02, a PEG ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.37%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.